Bliss GVS Pharma Limited (BOM:506197)

Market Cap	41.93B +257.5%
Revenue (ttm)	8.68B +7.2%
Net Income	1.09B +83.0%
EPS	10.19 +81.2%
Shares Out	105.79M
PE Ratio	38.89
Forward PE	n/a
Dividend	1.00 (0.26%)
Ex-Dividend Date	Feb 18, 2026

Volume	519,783
Open	384.00
Previous Close	381.10
Day's Range	374.45 - 399.00
52-Week Range	118.35 - 396.35
Beta	0.95
Analysts	n/a
Price Target	n/a
Earnings Date	May 12, 2026

About Bliss GVS Pharma

Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotion, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company also provide...

• Industry: Pharmaceutical Preparations
• Founded: 1984
• Employees: 966
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 506197

Financial Performance

In fiscal year 2025, Bliss GVS Pharma's revenue was 8.10 billion, an increase of 5.13% compared to the previous year's 7.70 billion. Earnings were 842.99 million, an increase of 11.72%.